Current Report Filing (8-k)
March 12 2019 - 8:39AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
March 12, 2019
SUNSHINE BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its
charter)
Colorado
|
000-52898
|
20-5566275
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer ID No.)
|
6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
(Address
of principal executive offices)
(514) 426-6161
(Issuer’s
Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[ ]
Item 7.01 Regulation FD Disclosure
Our Press Release relating to the availability of our new
product,
Essential 9
TM
on Amazon.ca is
attached as Exhibit 99.8 and is hereby incorporated as if set
forth.
Item 8.01 Other Events.
On
December 14, 2018, Health Canada issued NPN 80089663 through which
it authorized us to begin the manufacture and sale of our Essential
9
TM
product. Essential 9
TM
is a dietary
supplement tablet that contains a balanced formula of the 9
essential amino acids that the human body cannot make. Our product
is now available for purchase on www.amazon.ca.
Essential
9
TM
is a
dietary supplement tablet that contains a balanced formula of the 9
essential amino acids.
Like vitamins,
Essential Amino Acids cannot be made by the human body and must be
obtained through diet. Deficiency in one or more of the 9 Essential
Amino Acids can lead to loss of muscle mass, fatigue, weight gain
and reduced ability to build muscle mass in athletes. Our Essential
9
TM
product provides all 9 Essential Amino
Acids in freeform and in the proportions recommended by Health
Canada.
While
no assurances can be provided, we anticipate that Essential
9
TM
will
soon be available on
www.Amazon.com
.
Item 9.01 Financial Statements and Exhibits
(b)
Exhibits. The following exhibits are included in this
report:
Press Release
Announcing Availability of Essential 9
TM
on
Amazon.ca
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
SUNSHINE BIOPHARMA,
INC.
|
|
|
|
|
|
Dated: March 12,
2019
|
By:
|
/s/ Dr. Steve N
Slilaty
|
|
|
|
Dr.
Steve N Slilaty
|
|
|
|
Chief Executive
Officer
|
|